Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marker TherapeuticsFRA:GX1 -2.65%34 PB Ratio is 1.54 as of Jul. 16, 2026, which is 39% below its 10-year median of 2.51. GuruFocus rates FRA:GX1 with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,227 Biotechnology companies, Marker Therapeutics ranks better than 68.7% on this metric.
The historical rank and industry rank for Marker Therapeutics's PB Ratio or its related term are showing as below:
FRA:GX1'
s PB Ratio Range Over the Past 10 Years
Min: 0.11 Med: 2.51 Max: 184.2
Current: 1.7
During the past 13 years, Marker Therapeutics's highest PB Ratio was 184.20. The lowest was 0.11. And the median was 2.51.
FRA:GX1's PB Ratio is ranked better than 68.7% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:GX1: 1.70
During the past 12 months, Marker Therapeutics's average Book Value Per Share Growth Rate was -36.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -29.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Marker Therapeutics was 80.90% per year. The lowest was -68.70% per year. And the median was -24.40% per year.
Back to Basics: PB Ratio
Marker Therapeutics (FRA:GX1) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Marker Therapeutics PB Ratio Related Terms
Marker Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Marker Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Marker Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marker Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marker Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Marker Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Marker Therapeutics (FRA:GX1) has a PB Ratio of 1.54 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Marker Therapeutics and its competitors. This is 39% below median its historical median of 2.51. Over the past decade, Marker Therapeutics' PB Ratio has ranged from 0.11 to 184.20. According to the industry distribution chart, Marker Therapeutics ranks #384 out of 1227 companies in the Biotechnology industry, placing it in the top 31.3%.
Is Marker Therapeutics' PB Ratio too high?
Marker Therapeutics' current PB Ratio of 1.54 is 39% below median its 10-year median of 2.51. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 184.20. The Biotechnology industry median PB Ratio is 2.93. Marker Therapeutics' value of 1.54 is 47.4% below this industry median. Based on the distribution chart, Marker Therapeutics ranks #384 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Marker Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' PB Ratio compare to PLUR and VYNE?
According to the Biotechnology industry distribution chart, Marker Therapeutics ranks #384 out of 1227 companies for PB Ratio. This puts Marker Therapeutics in the upper half of its industry. The industry median PB Ratio is 2.93. Marker Therapeutics' value of 1.54 is 47.4% below this benchmark. Historically, Marker Therapeutics' own PB Ratio has ranged from 0.11 to 184.20 over the past decade. While the company's 10-year median is 2.51 vs. the industry median of 2.93, Marker Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marker Therapeutics's current PB Ratio of 1.54 is 47.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Marker Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marker Therapeutics's current PB Ratio is 1.54, which is 39% below median its own 10-year median of 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (FRA:GX1) has a current PB Ratio of 1.54. The current PB Ratio is 1.54, which is 39% below median its 10-year median of 2.51 and 47.4% below the Biotechnology industry median of 2.93. Marker Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Marker Therapeutics (FRA:GX1), the current PB Ratio is 1.54 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
34GF Score
Get the complete analysis for FRA:GX1
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GX1 has been successfully added to your 
